Browse Category

Analyst Forecasts News 22 December 2025

Amicus Therapeutics (FOLD) Stock on Dec. 22, 2025: BioMarin’s $14.50 Buyout, Latest News, Analyst Forecasts, and What’s Next

Amicus Therapeutics (FOLD) Stock on Dec. 22, 2025: BioMarin’s $14.50 Buyout, Latest News, Analyst Forecasts, and What’s Next

Dec. 22, 2025 — Amicus Therapeutics, Inc. (NASDAQ: FOLD) has abruptly shifted from a “rare-disease growth story” into a deal-driven stock, after BioMarin Pharmaceutical announced an all-cash agreement to acquire Amicus for $14.50 per share. With shares trading around $14.18
Rolls-Royce Holdings plc Stock (LSE: RR.) on 22 December 2025: Buybacks, Defence Momentum, SMR Tailwinds—and What Analysts Forecast Next

Rolls-Royce Holdings plc Stock (LSE: RR.) on 22 December 2025: Buybacks, Defence Momentum, SMR Tailwinds—and What Analysts Forecast Next

Rolls London, 22 December 2025 — Rolls-Royce Holdings plc (LSE: RR.; ADR: RYCEY) is ending the year as one of the UK market’s most closely watched industrial and defence-linked names, with investors balancing strong cash-generation signals against a share price
Commonwealth Bank of Australia Stock (ASX: CBA) on 22 December 2025: Latest News, Analyst Forecasts, Rate Outlook and What Investors Are Watching

Commonwealth Bank of Australia Stock (ASX: CBA) on 22 December 2025: Latest News, Analyst Forecasts, Rate Outlook and What Investors Are Watching

Commonwealth Bank of Australia (CBA) stock is ending 2025 in a familiar position: absolutely central to the Australian sharemarket, heavily owned, and fiercely debated. On 22 December 2025, CBA shares traded around A$158.49 in afternoon trade (prices delayed), modestly higher
1 11 12 13 14 15 43
Go toTop